Clinical Trial

A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)

Study acronym: LuCaRTE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to better understand people who have advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation. NSCLC is an advanced stage cancer of the lung, occurring due to mutations (changes) in the EGFR gene. The study will assess the participant demographic background (that is age, gender etc.), the treatments they receive, how well those treatments work, and their health outcomes.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-08-30 -> 2026-11-30 2026-08-04
minor Completion pushed: 2026-09-30 -> 2026-11-30 2026-08-04
Trial Details
NCT Number NCT07680907
Lead Sponsor Janssen-Cilag Farmaceutica Ltda.
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 250 participants
Start Date 2026-09-30
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-03